Pulmonary hypertension and liver transplantation

Cardiovascular Diseases and Liver Transplantation

Volumn , Issue , 2011, Pages 83-97

  Ramsay, Michael ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84864315129     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (67)

1. Mantz FA, Craig E. Portal axis thrombosis with spontaneous portacaval shunt and resultant cor pulmonale. Arch Pathol Lab Med 1951; 52:91-7.
2. Rodriguez-Roisin R, Krowka M, Hervé P, Fallon M. ERS Task Force Pulmonary-Hepatic Vascular Disorders (PHD) Scientific CommitTTE. Pulmonary-Hepatic Vascular Disorders. Eur Respir J 2004; 24:861-80.
3. Ramsay M. Portopulmonary hypertension and right heart failure in patients with Cirrhosis. Curr Opin Anaesthesiol 2010; 23:145-50.
4. Herve P, Lebrec D, Brenot F, Simonneau G, Humbert M, Sitbon O, Duroux P. Pulmonary vascular disorders in portal hypertension. Eur Resp J 1998; 11:1153-66.
5. Kawut SM, Krowka MJ, Trotter JF, Roberts KE, Benza RL, Badesch DB et al. Pulmonary Vascular Complications of Liver Disease Study Group. Clinical risk factors for portopulmonary hypertension. Hepatology 2008; 48:196-203.
6. Le Pavec J, Souza R, Herve P, Lebrec D, Savale L, Tcherakian C et al. Portopulmonary hypertension: Survival and prognostic factors. Am J Respir Crit Care Med 2008; 178:637-43.
7. Koch DG, Caplan M, Reuben A. Pulmonary hypertension after liver transplantation: Case presentation and review of the literature. Liver Transpl 2009; 15:407-12.
8. Ramsay M. Liver transplantation and pulmonary hypertension: pathophysiology and management strategies. Curr Opin Organ Transplant 2007; 12:274-80.
9. Schroeder RA, Ewing CA, Sitzman JV, Kuo PC.. Pulmonary expression of iNOS and HO-1 protein is upregulated in a rat model of prehepatic portal hypertension. Dig Dis Sci 2000; 45:2405-10
10. Ramsay M. Portopulmonary hypertension and hepatopulmonary syndrome and liver transplantation. Int Anesthesiol Clin 2006; 44:69-82.
11. Bernardi M, Gulberg V, Colantoni A, Trevisani F, Gasbarrini A, Gerbes AL. Plasma endothelin-1 and 3 in cirrhosis: relationship with systemic hemodynamics, renal function and neurohumeral systems. J Hepatol 1996, 24: 161-8.
12. Maruyama T, Ohsaki K, Shimoda S, Kaii Y, Harada M.. Thromboxane-dependent portopulmonary hypertension. Am J Med 2005; 118: 93-4.
13. Kaspar MD, Ramsay MA, Shuey CB Jr, Levy MF, Klintmalm GG. Severe pulmonary hypertension and amelioration of hepatopulmonary syndrome after liver transplantation. Liver Transpl Surg 1998; 4:177-9
14. Newman JH. Pulmonary hypertension. Am J Respir Care Med 2005; 172:1072-7
15. Roberts KE, Fallon MB, Krowka MD, Brown RS, Trotter JF, Peter I et al. Pulmonary Vascular Complications of Liver Disease Study Groupet. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med 2009; 179:835-42.
16. Roberts KE, Fallon MB, Krowka MJ, Benza RL, Knowles JA, Badesch DB et al. Pulmonary Vascular Complications of Liver Disease Study Group Serotonin transporter polymorphisms in patients with portopulmonary hypertension. Chest 2009; 135:1470-5.
17. Peng T, Zamanian R, Krowka MJ, Benza RL, Roberts KE, Taichman DB et al. Pulmonary Vascular Complications of Liver Disease Study Group. Biomarkers 2009;14:156-60.
18. Swanson KL, Krowka MJ. Arterial oxygenation associated with portopulmonary hypertension. Chest 2002;121:1869-75
19. Bernal V, Pascual I, Esquivias P, García-Gil A, Mateo JM, Lacambra I et al. N-Terminal brain natriuretic peptide as a diagnostic test in cirrhotic patients with pulmonary arterial hypertension. Transplant Proc 2009; 41:987-8.
20. Colle IO, Moreau R, Godinho E, Belghiti J, Ettori F, Cohen-Solal A et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation. Hepatology 2003; 37: 401-9.
21. Murray KF, Carithers RL Jr. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology 2005;41:1407-32.
22. Kim W, Krowka M, Plevak D, Lec J, Rettke SR, Frantz RP, Wiesner RH. Accuracy of Doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates. Liver Transpl 2000;6:453-8.
23. Farzaneh-Far R, McKeown BH, Dang D, Roberts J, Schiller NB, Foster E. Accuracy of Doppler-estimated pulmonary vascular resistance in patients before liver transplantation. Am J Cardiol 2008; 101:259-62.
24. Alqahtani SA, Fouad TR, Lee SS. Cirrhotic cardiomyopathy. Semin Liver Dis 2008;28:59-69
25. Afifi S, Shayan S, Al-Qamari A. Pulmonary hypertension and right ventricular function: interdependence in pathophysiology and management. Int Anesthesiol Clin 2009;47:97-120
26. Ricci GL, Melgosa MT, Burgos F, Valera JL, Pizarro S, Roca J et al. Assessment of acute pulmonary vascular reactivity in portopulmonary hypertension. Liver Transpl 2007; 13:1506-14.
27. Ota K, Shijo H, Kokawa H, Kubara K, Kim T, Akiyoshi N et al. Effects of nifedipine on hepatic venous pressure gradient and portal vein blood flow in patients with cirrhosis. J Gastroenterol Hepatol 1995; 10: 198-204.
28. Provencher S, Herve P, Jais X, Lebrec D, Humbert M, Simonneau G, Sitbon O. Deleterious effect of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology 2006; 130:120-6.
29. Findlay JY, Plevak DJ, Krowka MJ, Sack EM, Porayko MK. Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension. Liver Transpl Surg 1999; 5: 362-5.
30. Fix OK, Bass NM, De Marco T, Merriman RB. Long-term follow-up of portopulmonary hypertension: effect of treatment with epoprostenol. Liver Transpl 2007; 13: 875-85.
31. Krowka MJ, Frantz RP, McGoon MD, Severson C, Plevak DJ, Weisner RH. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999; 30: 641-48.
32. Kuo PC, Johnson LB, Plotkin JS, Howell CD, Bartlett ST, Rubin LJ. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation 1997; 63: 604-6.
33. Krug S, Sablotzki A, Hammerschmidt S, Wirtz H, Sevfarth HJ.Inhaled iloprost for the control of pulmonary hypertension. Vasc Health and Risk Management 2009; 5: 465-74.
34. Hoeper M, Seyfarth H, Hoeffken G, Wirtz H, Spiekerkoetter E, Pletz MW et al. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur Respir J 2007; 30: 1096-102.
35. Rex S, Missant C, Claus P, Buhre W, Wouters PF. Effects of inhaled iloprost on right ventricular contractility, right ventriculo-vascular coupling and ventricular interdependence: a randomized placebo-controlled trial in an experimental model of acute pulmonary hypertension. Crit Care 2008, 12: 1-13.
36. Minder S, Fischler M, Muelhaupt B, Zalunardo MP, Jenni R, Clavien PA, Speich R. Intravenous iloprost bridging to orthotopic liver transplantation in portopulmonary hypertension. Eur Respir J 2004; 24:703-7.
37. Benza RL, Rayburn BK, Tallaj JA, Pamboukian SV, Bourge RC. Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan. Chest 2008;134(1):139-45
38. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A et al. Bosentan therapy for pulmonary artery hypertension. N Engl J Med 2002;346:896-903.
39. Galiè N, Rubin Lj, Hoeper M, Jansa P, Al-Hiti H, Meyer G et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008;371(9630):2093-100
40. McGoon MD, Frost AE, Oudiz RJ, Badesch DB, Galie N, Olschewski H et al. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest 2009;135(1):122-9.
41. Gough M, White J. Sildenafil therapy is associated with improved hemodynamics in liver transplantation candidates with pulmonary artery hypertension. Liver Transpl 2009;15: 30-36.
42. Hemnes A, Robbins I. Sildenafil monotherapy in portopulmonary hypertension can facilitate liver transplantation. Liver Transpl 2009;15:15-19.
43. Montani D, Chaumais MC, Savale L, Natali D, Price LC, Jaïs X et al. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. Adv Ther 2009;26(9):813-25.
44. Wang H, Gong M, Bin Z, Dai A. Comparison of inhaled and intravenous milrinone in patients with pulmonary hypertension undergoing mitral valve surgery. Adv Ther 2009; 26:462-8.
45. Findlay JY, Harrison BA, Plevak DJ, Krowka MJ. Inhaled nitric oxide reduces pulmonary artery pressures in portopulmonary hypertension. Liver Transpl Surg 1999; 5:381-7
46. Ramsay MAE, Spikes C, East CA, et al. The perioperative management of portopulmonary hypertension with nitric oxide and epoprostenol. Anesthesiology 1999; 90:299-301.
47. Austin MJ, McDougall NI, Wendon JA, Sizer E, Knisely AS, Rela M et al. Safety and efficacy of combined use of sildenafil, bosentan, and iloprost before and after liver transplantation in severe portopulmonary hypertension. Liver Transpl 2008;14:287-91.
48. Tapper E, Knowles D, Heffron T, Lawrence EC, Csete M. Portopulmonary hypertension: imatinib as a novel treatment and the Emory experience with this condition. Transpl Proc 2009; 1:1969-71.
49. Swanson KL, Wiesner RH, Nyberg SL, Rosen CB, Krowka MJ. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups. Am J Transplant 2008; 8:2445-53.
50. Swanson KL, Krowka MJ. Screen for portopulmonary hypertension, especially in liver transplant candidates. Cleve Clin J Med 2008;75:121-36.
51. Ashfaq M, Chinnakotla S, Rodgers L.Ausloos K, Saadeh S, Klintmalm GB et al. The impact of treatment of portopulmonary hypertension on survival following liver transplantation. Am J Transpl 2007; 7:1258-64.
52. Krowka M, Mandell M, Ramsay M, Kawut SM, Fallon MB, Manzarbeitia C et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl 2004; 10:174-82.
53. Naeije R, Huez S. Expert opinion on available options treating pulmonary arterial hypertension. Expert Opin Pharmacother 2007; 8: 2247-65.
54. Porres-Aguilar M, Zuckerman M, Figueroa-Casas J, Krowka M. Portopulmonary hypertension: state of the art. Ann Hepatol 2008; 7: 321-30.
55. Zamanian RT, Haddad F, Doyle RL, Weinacker A. Management strategies for patients with pulmonary hypertension in the intensive care unit. Crit Care Med 2007;35:2037-50
56. Ramsay M. The reperfusion syndrome: have we made any progress? Liver Transpl 2008; 14: 412-4.
57. Paugam-Burtz C, Kavafyan J, Merckx P, Dahmani S, Sommacale D, Ramsay M et al. Postreperfusion syndrome during liver transplantation for cirrhosis: outcome and predictors. Liver Transpl 2009; 15: 522-9
58. Braun EB, Palin CA, Hogue CW. Vasopressin during spinal anesthesia in a patient with primary pulmonary hypertension treated with intravenous epoprostenol. Anesth Analg 2004; 99:36-37.
59. Sugimachi K, Soejima Y, Morita S, Ueda S, Fukuhara T, Nagata S et al. Rapid normalization of portopulmonary hypertension after living donor liver transplantation. Transpl Proc 2009; 41:1976-8.
60. Umeda N, Kamath P. Hepatopulmonary syndrome and portopulmonary hypertension. Hepatol Res 2009;39:1020-2.
61. Swanson K, Wiesner R, Nyberg S. Rosen CB, Krowka MJ. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups. Am J Transpl 2008;8:2445-53.
62. Singh C, Sager J. Pulmonary complications of cirrhosis. Med Clin N Am 2009; 95:871-83.
63. Yeshua H, Blendis L, Oren R. Pulmonary manifestations of liver diseases. Sem Cardiothorac Vasc Anesth 2009;13:60-9.
64. Golbin J, Krowka M. Portopulmonary hypertension. Clin Chest Med 2007; 28: 203-18.
65. Krowka MJ, Mandell MS, Ramsay MA, Kawut SM, Fallon MB, Manzarbeitia C et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl 2004;10(2):174-82.
66. Krowka M, Fallon M, Mulligan D, Gish RG. Model for end-stage liver disease (MELD) exception for portopulmonary hypertension. Liver Transpl 2006;12: S114-S116.
67. Grannas G, NeippM, Hoeper M, Gottlieb J, Luck R, Becker T.et al. Indications for and outcomes after combined lung and liver transplantation: a single center experience on 13 consecutive cases. Transplantation 2008; 85 (4):524-31.